ADPKD as a Temporally Dynamic Disease: Implications for Biomarkers, Trial Design, and Therapeutic Targeting
- 1Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- 2Mayo Translational PKD Center, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) has traditionally been conceptualized as a structurally progressive disease, with cyst growth driving loss of kidney function. This view has led to the widespread use of total kidney volume for risk stratification and clinical trial design. However, longitudinal human studies and experimental models indicate that the relationship between structure, function, and underlying biology changes over the disease course. Earlier disease is characterized by prominent cystic, proliferative, and metabolic activity together with early inflammatory responses; inflammatory and injury-repair processes become increasingly prominent during intermediate disease, whereas fibrosis and loss of functional parenchyma assume a greater role later as kidney function declines. These processes overlap rather than define discrete stages, and their timing and relative contributions likely vary among individuals. This review proposes that ADPKD be considered as a temporally dynamic disease and examines the implications of this framework for biomarker development, clinical trial design, and therapeutic targeting. Such a framework emphasizes the need to complement structural measures with biomarkers of evolving biology, to identify biological transitions prospectively, and to align therapeutic targets and end points with the processes contributing meaningfully to progression in the population being studied.
Related
- Hyperinflammation and immunomodulation in influenza, SARS-CoV-2 and syncytial respiratory virus infection in adults: from innate immune responses and biomarkers to clinical and therapeutic implications
- Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting
- Beyond static species distribution models: temporally dynamic, spatially nested models reduce extrapolation for future projections
- Neutrophil Extracellular Traps at the Asthma + COPD Interface: Mechanisms, Experimental Models, and Therapeutic Targeting
- Special Issue “Molecular Mechanisms and Therapeutic Targeting of Inflammatory Complications”
BibTeX
@article{irazabal2026adpkd,
title = {{ADPKD as a Temporally Dynamic Disease: Implications for Biomarkers, Trial Design, and Therapeutic Targeting}},
author = {Maria V Irazabal},
journal = {Kidney International Reports},
year = {2026},
month = sep,
doi = {10.1016/j.ekir.2026.107113},
url = {https://doi.org/10.1016/j.ekir.2026.107113},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - ADPKD as a Temporally Dynamic Disease: Implications for Biomarkers, Trial Design, and Therapeutic Targeting
AU - Maria V Irazabal
PY - 2026
DA - 2026/09/26
JO - Kidney International Reports
DO - 10.1016/j.ekir.2026.107113
UR - https://doi.org/10.1016/j.ekir.2026.107113
AB - Autosomal dominant polycystic kidney disease (ADPKD) has traditionally been conceptualized as a structurally progressive disease, with cyst growth driving loss of kidney function. This view has led to the widespread use of total kidney volume for risk stratification and clinical trial design. However, longitudinal human studies and experimental models indicate that the relationship between structure, function, and underlying biology changes over the disease course. Earlier disease is characterized by prominent cystic, proliferative, and metabolic activity together with early inflammatory responses; inflammatory and injury-repair processes become increasingly prominent during intermediate disease, whereas fibrosis and loss of functional parenchyma assume a greater role later as kidney function declines. These processes overlap rather than define discrete stages, and their timing and relative contributions likely vary among individuals. This review proposes that ADPKD be considered as a temporally dynamic disease and examines the implications of this framework for biomarker development, clinical trial design, and therapeutic targeting. Such a framework emphasizes the need to complement structural measures with biomarkers of evolving biology, to identify biological transitions prospectively, and to align therapeutic targets and end points with the processes contributing meaningfully to progression in the population being studied.
SN - 2468-0249
ER -